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OBJECTIVES: To determine the cost-effectiveness of interventions for major depres-
sion in Thailand. METHODS: A microsimulation model was developed to describe 
the course of disease in individuals. Model inputs included Thai data on disease 
parameters and costs while impact measures are derived from a systematic review and 
meta-analysis of the international literature. Results are presented as cost (Thai Baht) 
per disability adjusted life-year (DALY) averted, compared to the null scenario (do 
nothing). Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for 
treatment of episodes plus a 6 month continuation phase and for maintenance treat-
ment over 5 years of follow-up. Cognitive behavioral therapy (CBT) was analyzed for 
episodic treatment and for 5-year maintenance treatment. RESULTS: The incremental 
cost-effectiveness ratios (ICER) of ﬂ uoxetine for episodic treatment with or without a 
continuation or maintenance phase are just below one times GDP per capita in Thailand 
of 110,000 Baht. CBT during an episode of depression (ICER = 39,000) is more cost-
effective than medications (ICER = 88,000); a maintenance version of CBT is the most 
cost-effective option with an ICER of 27,000. Episodic drug treatment has the lowest 
cost (250 Million Baht) and averts 3000 DALYs. Episodic treatment with CBT, which 
has an ongoing effect for 1.5 years, costs 100 Million Baht more than drug treatment 
but it averts more than 6000 DALYs compared to drugs. CONCLUSIONS: CBT is the 
most cost-effective treatment option for both episodic and maintenance treatment. 
Maintenance treatment is the more cost-effective of the two. However, there is cur-
rently a lack of mental health personal, especially psychiatrists and psychologists, who 
would be expected to deliver CBT in Thailand. Antidepressant drugs are quite a bit 
less effective but also less costly than CBT. 
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OBJECTIVES: To determine the optimal treatment package, including drug and non 
drug interventions, for schizophrenia in Thailand. METHODS: A Markov model was 
used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, 
olanzapine, clozapine and family interventions. Health outcomes were measured in 
disability adjusted life-years. We considered health outcomes from a change in disease 
severity; extrapyradimal symptoms and weight gain as side effects; and a reduction in 
suicide (for clozapine only). Intervention costs included treatment cost, hospitalization 
cost as well as time and travel cost of patients and families. Uncertainty was evaluated 
using multivariate Monte Carlo simulation. As a generic version of risperidone is 
expected on the market soon, a sensitivity analysis of varying costs of risperidone was 
undertaken. RESULTS: The cost-effectiveness results indicate generic risperidone, 
assuming a cost of 4 baht per 2-mg tablet will improve health outcomes and save costs 
if replacing the currently predominant treatment of typical drugs. The ideal combina-
tion of treatments is risperidone as ﬁ rst line treatment (dominant intervention), adding 
family interventions for all patients (Incremental cost-effectiveness ratio of 2000 baht/
DALY) and adding clozapine to severe patients (an estimated 33% of patients). This 
addition has an incremental cost-effectiveness ratio of 290,000 baht/DALY, which is 
still less than three times GDP per capita. CONCLUSIONS: The introduction of 
generic risperidone will lead to more efﬁ cient outcomes and lower costs if it can be 
produced for less than 10 baht per 2-mg tablet. Providing family interventions for all 
patients and treating more severe patients with clozapine can further improve out-
comes of Thai patients with schizophrenia in a cost-effective manner. 
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OBJECTIVES: Adequate duration of antidepressant therapy is essential for the treat-
ment of major depressive disorder (MDD). This study examined the association 
between medication persistence and hospitalization and emergency room (ER) visit 
for high-cost patients with MDD in the usual clinical setting. METHODS: In a large 
US commercial managed-care claims database, 8177 MDD patients (18 to 64 years 
old) were initiated on duloxetine or venlafaxine XR during the calendar year 2006. 
All of the patients had no active prescription of study medications for 6 months prior 
to initiation and had continuous enrollment for 12 months prior to and post-
medication initiation. High-cost patients were deﬁ ned as patients whose total treat-
ment costs in the prior 1 year were above the median of total costs for all MDD 
patients in 2005 (n = 5093). After propensity-score matching on observed variables 
known to affect medication choices, 1714 duloxetine patients and an equal number 
of venlafaxine XR patients were included for this analysis. Medication persistence was 
deﬁ ned as the length of therapy without exceeding a 15-day gap. Logistic regression 
analyses were used to examine the associations between medication persistence and 
health-care utilization in the year following treatment initiation. RESULTS: In the 
post 1 year, duloxetine patients stayed on the medication signiﬁ cantly longer (119.5 
vs. 110.4 days, P = 0.047) than venlafaxine XR patients. Treatment persistence >3 
months was signiﬁ cantly associated with reduced odds of psychiatric hospitalization 
(OR = 0.46, 95% CI = 0.37–0.58), nonpsychiatric hospitalization (OR = 0.77, 95% 
CI = 0.64–0.92), and ER visit (OR = 0.69, 95% CI = 0.60–0.79). Treatment differences 
in health-care utilization were not statistically signiﬁ cant. These ﬁ ndings had no 
essential changes with adjustment for demographics, comorbid conditions, and prior 
health-care utilization and separate analyses for duloxetine and venlafaxine XR 
patients. CONCLUSIONS: Duloxetine therapy appears to have longer persistence 
than venlafaxine XR for high-cost patients with MDD. Medication persistence >3 
months is associated with reduced hospitalization and ER visit. 
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OBJECTIVES: Adherence and persistence to prescribed medication is important in 
the management of major depressive disorder (MDD). This study compared adherence 
and persistence between duloxetine and escitalopram among high health-care utilizers 
with MDD. METHODS: In a large US commercial managed-care claims database, 
10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n = 4542) or 
escitalopram (n = 6261) during the calendar year 2006 were identiﬁ ed. All of the 
patients had no recorded prescription of study medications for 6 months prior to 
initiation and had continuous enrollment for 12 months prior to and post-medication 
initiation. High health-care utilizers (duloxetine, n = 3113; escitalopram, n = 3157) 
were deﬁ ned as patients whose total treatment costs in the prior 1 year were above 
the median of total costs for all MDD patients in 2005. Adherence was deﬁ ned as 
Medication Possession Ratio (MPR) ≥0.8, and persistence was deﬁ ned as the length 
of therapy without exceeding a 30-day gap. Statistical analyses included chi-square 
test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In 
the post 6 months (6M) and 12 months (12M), adherence rates were signiﬁ cantly 
higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalo-
pram-treated patients (6M 47.4% and 12M 31.7%) (P-values < 0.001). Duloxetine-
treated patients also stayed on the medication signiﬁ cantly longer (6M 115.9 days and 
12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 
days) (P-values < 0.001). Results were essentially unchanged with adjustment for 
demographics, comorbid conditions, prior medications use, and health-care utiliza-
tion, resulting in duloxetine therapy maintaining its better adherence and longer 
persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear 
to be more adherent and have a longer stay on the medication than escitalopram-
treated patients for high resources utilizers. Further research is needed to examine 
clinical and economic beneﬁ ts of better adherence and persistence with duloxetine 
therapy. 
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OBJECTIVES: Treatment discontinuation is an important effectiveness measure for 
evaluating antipsychotic treatment, yet is typically assessed only on a high level (e.g., 
“lack of efﬁ cacy,” “adverse event,” or “patient decision”). The RAD-I was developed 
as a structured interview assessing patient’s perspective regarding speciﬁ c reasons for 
antipsychotic discontinuation and continuation and the RAD-Q as a questionnaire 
assessing clinician’s perspective. This study assessed the validity of the RAD measures 
in a randomized clinical trial. METHODS: The RAD was assessed at baseline (refer-
ring to medications prior to the trial) and endpoint (referring to discontinuation/
continuation of study drug) in a 12-week schizophrenia clinical trial. To assess its 
psychometric properties, we examined content validity, discriminate validity, and 
agreement between RAD scales using endpoint data (N = 158). RESULTS: Of 29 
potential primary reasons for medication discontinuation, the most common was 
insufﬁ cient improvement/worsening of positive symptoms (24%) followed by adverse 
events (22%). A high level of concurrent validity was observed, as 89% of patients 
discontinuing medication due to “lack of efﬁ cacy” (87%, “adverse events”) per the 
standard trial form had lack of efﬁ cacy (“adverse events”) as a primary or very 
important reason on the RAD. Patients indicating lack of improvement/worsening of 
positive symptoms as a primary reason for medication discontinuation on the RAD 
had signiﬁ cantly less improvement in PANSS positive score than patients not reporting 
this as a reason. Similar results were observed for the RAD mood items (per MADRS) 
and functional status (per QLS) as well as for corresponding analyses assessing reasons 
for continuation. Agreement between the clinician and patient scores was high (range 
73% to 100%). CONCLUSIONS: This initial psychometric assessment suggests the 
RAD is a valid tool for gathering detailed information regarding reasons for antipsy-
